Phase II trial of volasertib (BI 6727) versus chemotherapy (CT) in platinum-resistant/refractory ovarian cancer (OC)

被引：0
|
作者：
Pujade-Lauraine, Eric
Weber, Beatrice E.
Ray-Coquard, Isabelle
Vergote, Ignace
Selle, Frederic
Del Campo, Jose Maria
Sufliarsky, Jozef
Tschoepe, Inga
Chesa, Pilar Garin
Nazabadioko, Serge
Pilz, Korinna
Joly, Florence
机构：
[1] Hop Hotel Dieu, AP HP, Unite Oncol Med, F-75181 Paris, France
[2] Ctr Alexis Vautrin, Vandoeuvre Les Nancy, France
[3] Ctr Leon Berard, F-69373 Lyon, France
[4] Katholieke Univ Leuven, Univ Hosp Leuven, Leuven Canc Inst, Leuven, Belgium
[5] Katholieke Univ Leuven, Univ Hosp Leuven, Leuven, Belgium
[6] Hop Tenon, F-75970 Paris, France
[7] Vall dHebron Inst Oncol, Barcelona, Spain
[8] Natl Canc Inst, Bratislava, Slovakia
[9] Boehringer Ingelheim GmbH & Co KG, Reims, France
[10] Boehringer Ingelheim GmbH & Co KG, Vienna, Austria
[11] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany
[12] Ctr Francois Baclesse, F-14021 Caen, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5504
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II trial of voreloxin in women with platinum-resistant ovarian cancer
    Hirte, H. W.
    McGuire, W.
    Edwards, R.
    Husain, A.
    Hoskins, P.
    Michels, J.
    Matulonis, U.
    Sexton, C.
    Michelson, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: A gynecologic oncology group phase II trial
    Markman, M
    Blessing, JA
    Moore, D
    Ball, H
    Lentz, SS
    GYNECOLOGIC ONCOLOGY, 1998, 69 (03) : 226 - 229
  • [3] A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer
    Anda M. Vlad
    Raluca A. Budiu
    Diana E. Lenzner
    Yun Wang
    Julia A. Thaller
    Kelly Colonello
    Peggy A. Crowley-Nowick
    Joseph L. Kelley
    Fredric V. Price
    Robert P. Edwards
    Cancer Immunology, Immunotherapy, 2010, 59 : 293 - 301
  • [4] A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer
    Vlad, Anda M.
    Budiu, Raluca A.
    Lenzner, Diana E.
    Wang, Yun
    Thaller, Julia A.
    Colonello, Kelly
    Crowley-Nowick, Peggy A.
    Kelley, Joseph L.
    Price, Fredric V.
    Edwards, Robert P.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (02) : 293 - 301
  • [5] Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study
    Pujade-Lauraine, Eric
    Selle, Frederic
    Weber, Beatrice
    Ray-Coquard, Isabelle-Laure
    Vergote, Ignace
    Sufliarsky, Jozef
    Del Campo, Josep Maria
    Lortholary, Alain
    Lesoin, Anne
    Follana, Philippe
    Freyer, Gilles
    Pardo, Beatriz
    Vidal, Laura
    Tholander, Bengt
    Gladieff, Laurence
    Sassi, Mouna
    Garin-Chesa, Pilar
    Nazabadioko, Serge
    Marzin, Kristell
    Pilz, Korinna
    Joly, Florence
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (07) : 706 - +
  • [6] Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer
    Walsh, Christine S.
    Kamrava, Mitchell
    Rogatko, Andre
    Kim, Sungjin
    Li, Andrew
    Cass, Ilana
    Karlan, Beth
    Rimel, Bobbie J.
    PLOS ONE, 2021, 16 (06):
  • [7] Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or - Refractory Ovarian Cancer
    Liu, Joyce F.
    Ray-Coquard, Isabelle
    Selle, Frederic
    Poveda, Andres M.
    Cibula, David
    Hirte, Hal
    Hilpert, Felix
    Raspagliesi, Francesco
    Gladieff, Laurence
    Harter, Philipp
    Siena, Salvatore
    del Campo, Josep Maria
    Tabah-Fisch, Isabelle
    Pearlberg, Joseph
    Moyo, Victor
    Riahi, Kaveh
    Nering, Rachel
    Kubasek, William
    Adiwijaya, Bambang
    Czibere, Akos
    Naumann, R. Wendel
    Coleman, Robert L.
    Vergote, Ignace
    MacBeath, Gavin
    Pujade-Lauraine, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (36) : 4345 - +
  • [8] Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer.
    Vanderstichele, Adriaan
    Van Nieuwenhuysen, Els
    Han, Sileny
    Concin, Nicole
    Van Gorp, Toon
    Berteloot, Patrick
    Neven, Patrick
    Busschaert, Pieter
    Lambrechts, Diether
    Vergote, Ignace
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer
    Shibani Nicum
    Naomi McGregor
    Rachel Austin
    Linda Collins
    Susan Dutton
    Iain McNeish
    Rosalind Glasspool
    Marcia Hall
    Rene Roux
    Agnieszka Michael
    Andrew Clamp
    Gordon Jayson
    Rebecca Kristeleit
    Susana Banerjee
    Anita Mansouri
    British Journal of Cancer, 2024, 130 : 941 - 950
  • [10] Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer
    Nicum, Shibani
    Mcgregor, Naomi
    Austin, Rachel
    Collins, Linda
    Dutton, Susan
    Mcneish, Iain
    Glasspool, Rosalind
    Hall, Marcia
    Roux, Rene
    Michael, Agnieszka
    Clamp, Andrew
    Jayson, Gordon
    Kristeleit, Rebecca
    Banerjee, Susana
    Mansouri, Anita
    BRITISH JOURNAL OF CANCER, 2024, 130 (06) : 941 - 950
12345